Managing inpatient hyperglycaemia and initiating sodium-glucose cotransporter 2 inhibitor therapy in the setting of diabetes and acute coronary syndrome.
Sarah A HitchenNick Si Rui LanAdam L HortJames M RankinP Gerry FeganBu B YeapPublished in: Internal medicine journal (2021)
We previously showed that implementing algorithms for managing diabetes in acute coronary syndrome was associated with improved inpatient glycaemic control and increased sodium-glucose cotransporter 2 (SGLT2) inhibitor prescriptions. The present study performed 1 year later found that inpatient hyperglycaemia had relapsed to pre-intervention rates, although SGLT2 inhibitor prescriptions remained increased. We discuss the challenges of improving inpatient glycaemic control.
Keyphrases
- acute coronary syndrome
- type diabetes
- palliative care
- mental health
- acute care
- cardiovascular disease
- percutaneous coronary intervention
- glycemic control
- randomized controlled trial
- antiplatelet therapy
- machine learning
- acute lymphoblastic leukemia
- acute myeloid leukemia
- diffuse large b cell lymphoma
- multiple myeloma
- stem cells
- adipose tissue
- deep learning
- metabolic syndrome
- cell therapy
- mesenchymal stem cells
- weight loss